Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RPID Stock Summary
In the News

Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.63% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
LOWELL, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2022 financial results prior to the market open on Friday, March 3, 2023.

Rapid Micro Biosystems to Present at 41st Annual J.P. Morgan Healthcare Conference
LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference.

Rapid Micro Biosystems, Inc. (RPID) Q3 2022 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Mike Beaulieu - Investor Relations Rob Spignesi - Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Stephanie Yan - Cowen Operator Hello. My name is Lisa and I will be your conference operator today.

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.70% and 20.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Hill International, Rapid Micro Biosystems See Activist Investor Action
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Rapid Micro Biosystems, Inc. (RPID) CEO Rob Spignesi on Q2 2022 Results - Earnings Call Transcript
Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Mike Beaulieu - CFA Vice President, Investor Relations & Corporate Communications Rob Spignesi - Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Stephanie Yan - Cowen Rachel Cascio - JPMorgan Operator Ladies and gentlemen, thank you for standing by and welcome to the Rapid Micro Biosystems Second Quarter 2022 Earnings Conference Call. I would now like to turn the call over to Mike Beaulieu, Investor Relations.

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems Inc. (RPID) CEO Robert Spignesi on Q1 2022 Results - Earnings Call Transcript
Rapid Micro Biosystems Inc. (NASDAQ:RPID ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Noah Burhance - JPMorgan Operator Good day, and thank you for standing by. Welcome to the Rapid Micro Biosystems First Quarter 2022 Earnings Conference Call.

Rapid Micro Biosystems to Announce First Quarter 2022 Financial Results on May 10, 2022
LOWELL, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2022 financial results on Tuesday, May 10, 2022, prior to the market open.
RPID Financial details
RPID Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
Revenue per share | 0.61 | 0.6 | 0.86 | 0.4 | |
Net income per share | -0.79 | -1.38 | -2.73 | -1.43 | |
Operating cash flow per share | -0.78 | -1.15 | -2.04 | -1.38 | |
Free cash flow per share | -0.85 | -1.18 | -2.04 | -1.54 | |
Cash per share | 0.46 | 1.67 | 7.18 | 2.56 | |
Book value per share | -0.03 | 0.92 | 8.2 | 3.87 | |
Tangible book value per share | -0.03 | 0.92 | 8.2 | 3.87 | |
Share holders equity per share | -0.03 | 0.92 | 8.2 | 3.87 | |
Interest debt per share | 0.75 | 1.05 | -0.1 | 0.23 | |
Market cap | 577.01M | 577.01M | 286.89M | 47.97M | |
Enterprise value | 582.35M | 571.74M | 108.5M | 28.88M | |
P/E ratio | -27.25 | -15.56 | -3.9 | -0.79 | |
Price to sales ratio | 34.94 | 35.89 | 12.35 | 2.8 | |
POCF ratio | -27.29 | -18.62 | -5.22 | -0.82 | |
PFCF ratio | -25.26 | -18.21 | -5.22 | -0.73 | |
P/B Ratio | -795.87 | 23.25 | 1.3 | 0.29 | |
PTB ratio | -795.87 | 23.25 | 1.3 | 0.29 | |
EV to sales | 35.27 | 35.56 | 4.67 | 1.69 | |
Enterprise value over EBITDA | -34.44 | -17.87 | -1.46 | -0.51 | |
EV to operating cash flow | -27.54 | -18.45 | -1.97 | -0.49 | |
EV to free cash flow | -25.49 | -18.04 | -1.97 | -0.44 | |
Earnings yield | -0.04 | -0.06 | -0.26 | -1.27 | |
Free cash flow yield | -0.04 | -0.05 | -0.19 | -1.36 | |
Debt to equity | -44.71 | 1.82 | 0.09 | 0.16 | |
Debt to assets | 1.02 | 0.65 | 0.08 | 0.14 | |
Net debt to EBITDA | -0.32 | 0.16 | 2.39 | 0.34 | |
Current ratio | 2.24 | 4 | 12.01 | 7.27 | |
Interest coverage | -7.85 | -8.86 | 17.82 | -35.56 | |
Income quality | 1 | 0.84 | 0.75 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.54 | 0.62 | 0.77 | 1.57 | |
Research and developement to revenue | 0.33 | 0.41 | 0.42 | 0.75 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.08 | 0.02 | 0 | 0.12 | |
Capex to revenue | -0.1 | -0.04 | 0 | -0.39 | |
Capex to depreciation | -1.16 | -0.46 | -0.01 | -2.38 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.08 | 0.23 | |
Graham number | 0.69 | 5.34 | 22.42 | 11.16 | |
ROIC | -5.34 | -5.71 | 0.4 | -0.48 | |
Return on tangible assets | -0.67 | -0.53 | -0.3 | -0.32 | |
Graham Net | -0.5 | 0.32 | 6.86 | 2.28 | |
Working capital | 13.08M | 46.61M | 199.96M | 119.53M | |
Tangible asset value | -725K | 24.82M | 220.98M | 164.17M | |
Net current asset value | -8.8M | 16.97M | 197.94M | 112.1M | |
Invested capital | -24.56 | 1 | 0 | 0.05 | |
Average receivables | 0 | 5.35M | 5.39M | 5.19M | |
Average payables | 0 | 3.84M | 4.21M | 4.69M | |
Average inventory | 0 | 7.36M | 12.32M | 18.43M | |
Days sales outstanding | 108.74 | 131.32 | 78.63 | 114.38 | |
Days payables outstanding | 69.99 | 67.53 | 46.48 | 77.17 | |
Days of inventory on hand | 125.37 | 135.51 | 184.67 | 301.22 | |
Receivables turnover | 3.36 | 2.78 | 4.64 | 3.19 | |
Payables turnover | 5.22 | 5.4 | 7.85 | 4.73 | |
Inventory turnover | 2.91 | 2.69 | 1.98 | 1.21 | |
ROE | 29.2 | -1.49 | -0.33 | -0.37 | |
Capex per share | -0.06 | -0.03 | 0 | -0.16 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.12 | 0.1 | 0.09 | 0.11 | 0.1 | |
Net income per share | -0.35 | -0.35 | -0.31 | -0.38 | -0.39 | |
Operating cash flow per share | -0.31 | -0.4 | -0.35 | -0.36 | -0.27 | |
Free cash flow per share | -0.31 | -0.45 | -0.4 | -0.39 | -0.29 | |
Cash per share | 4.62 | 3.84 | 3.39 | 2.7 | 2.56 | |
Book value per share | 5.28 | 4.91 | 4.59 | 4.21 | 3.87 | |
Tangible book value per share | 5.28 | 4.91 | 4.59 | 4.21 | 3.87 | |
Share holders equity per share | 5.28 | 4.91 | 4.59 | 4.21 | 3.87 | |
Interest debt per share | 0 | 0.19 | 0.2 | 0.21 | 0.21 | |
Market cap | 445.37M | 286.52M | 182.72M | 137.33M | 47.97M | |
Enterprise value | 266.98M | 232.03M | 141.46M | 119.72M | 28.88M | |
P/E ratio | -7.62 | -4.8 | -3.49 | -2.1 | -0.73 | |
Price to sales ratio | 85.52 | 68.88 | 47.34 | 28.98 | 10.97 | |
POCF ratio | -34.56 | -17.05 | -12.19 | -9.09 | -4.12 | |
PFCF ratio | -34.56 | -14.96 | -10.76 | -8.23 | -3.85 | |
P/B Ratio | 2.02 | 1.38 | 0.94 | 0.77 | 0.29 | |
PTB ratio | 2.02 | 1.38 | 0.94 | 0.77 | 0.29 | |
EV to sales | 51.26 | 55.78 | 36.65 | 25.26 | 6.6 | |
Enterprise value over EBITDA | -18.88 | -16.19 | -10.87 | -7.97 | -1.96 | |
EV to operating cash flow | -20.72 | -13.81 | -9.44 | -7.93 | -2.48 | |
EV to free cash flow | -20.72 | -12.11 | -8.33 | -7.17 | -2.32 | |
Earnings yield | -0.03 | -0.05 | -0.07 | -0.12 | -0.34 | |
Free cash flow yield | -0.03 | -0.07 | -0.09 | -0.12 | -0.26 | |
Debt to equity | 0.09 | 0.11 | 0.11 | 0.13 | 0.16 | |
Debt to assets | 0.08 | 0.1 | 0.1 | 0.11 | 0.14 | |
Net debt to EBITDA | 12.62 | 3.8 | 3.17 | 1.17 | 1.29 | |
Current ratio | 12.01 | 12.57 | 13.45 | 9.5 | 7.27 | |
Interest coverage | 766.11 | -1.36K | -1.41K | -29.37 | -20.77 | |
Income quality | 0.88 | 1.13 | 1.14 | 0.92 | 0.71 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.11 | 1.46 | 1.66 | 1.52 | 1.63 | |
Research and developement to revenue | 0.55 | 0.85 | 0.77 | 0.63 | 0.78 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.14 | 0.13 | 0.11 | 0.07 | |
Capex to revenue | 0 | -0.57 | -0.52 | -0.33 | -0.19 | |
Capex to depreciation | 0 | -4.2 | -2.91 | -2.16 | -0.94 | |
Stock based compensation to revenue | 0.13 | 0.24 | 0.33 | 0.14 | 0.25 | |
Graham number | 6.44 | 6.25 | 5.64 | 6.03 | 5.81 | |
ROIC | 0.12 | -0.15 | -0.12 | -0.12 | -0.13 | |
Return on tangible assets | -0.06 | -0.06 | -0.06 | -0.08 | -0.09 | |
Graham Net | 4.42 | 3.58 | 3.22 | 2.49 | 2.28 | |
Working capital | 199.96M | 172.03M | 158.73M | 129.37M | 119.53M | |
Tangible asset value | 220.98M | 207.07M | 194.97M | 179.02M | 164.17M | |
Net current asset value | 197.94M | 163.92M | 150.31M | 121.68M | 112.1M | |
Invested capital | 0 | 0.04 | 0.04 | 0.05 | 0.05 | |
Average receivables | 5.01M | 4.54M | 4.2M | 4.52M | 5.04M | |
Average payables | 3.1M | 3.75M | 3.19M | 3.25M | 4.55M | |
Average inventory | 14.92M | 16.69M | 19.5M | 21.11M | 21.06M | |
Days sales outstanding | 86.49 | 88.2 | 100.87 | 89.53 | 110.47 | |
Days payables outstanding | 45.54 | 52.51 | 49.99 | 43.85 | 70.04 | |
Days of inventory on hand | 180.96 | 262 | 377.16 | 249.99 | 273.38 | |
Receivables turnover | 1.04 | 1.02 | 0.89 | 1.01 | 0.81 | |
Payables turnover | 1.98 | 1.71 | 1.8 | 2.05 | 1.29 | |
Inventory turnover | 0.5 | 0.34 | 0.24 | 0.36 | 0.33 | |
ROE | -0.07 | -0.07 | -0.07 | -0.09 | -0.1 | |
Capex per share | 0 | -0.06 | -0.05 | -0.04 | -0.02 |
RPID Frequently Asked Questions
What is Rapid Micro Biosystems, Inc. stock symbol ?
Rapid Micro Biosystems, Inc. is a US stock , located in Lowell of Ma and trading under the symbol RPID
Is Rapid Micro Biosystems, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8
What is RPID stock prediction ?
What is Rapid Micro Biosystems, Inc. stock quote today ?
Rapid Micro Biosystems, Inc. stock price is $1.25 today.
Is Rapid Micro Biosystems, Inc. stock public?
Yes, Rapid Micro Biosystems, Inc. is a publicly traded company.